Genocea begins Phase II dose optimisation trial for GEN-003 to treat HSV-2

US-based biopharmaceutical firm Genocea Biosciences has initiated a Phase II dose optimisation trial for GEN-003, its immunotherapy candidate for treatment of herpes simplex-type 2 (HSV-2).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news